These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19601748)

  • 1. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
    Marson CM
    Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: latest developments, trends and prospects.
    Moradei O; Maroun CR; Paquin I; Vaisburg A
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):529-60. PubMed ID: 16178777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From discovery to the coming generation of histone deacetylase inhibitors.
    Yoshida M; Matsuyama A; Komatsu Y; Nishino N
    Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure and function of histone deacetylases: the target for anti-cancer therapy.
    Zhang Y; Fang H; Jiao J; Xu W
    Curr Med Chem; 2008; 15(27):2840-9. PubMed ID: 18991639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
    Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors: gathering pace.
    Carey N; La Thangue NB
    Curr Opin Pharmacol; 2006 Aug; 6(4):369-75. PubMed ID: 16781195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors open new doors in cancer therapy.
    McLaughlin F; La Thangue NB
    Biochem Pharmacol; 2004 Sep; 68(6):1139-44. PubMed ID: 15313411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.